1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map \< 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin \> 10 mg/dl 3. platelet count \< 50,000/ml 4. subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer diagnosis or treatment in the past 1 year 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive \>24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)

1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map \< 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin \> 10 mg/dl 3. platelet count \< 50,000/ml 4. subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer diagnosis or treatment in the past 1 year 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive \>24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)

evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. serum bilirubin > 10 mg/dl platelet count < 50,000/ml subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) history of metastatic cancer diagnosis or treatment in the past 1 year history of previous treatments with mscs or other cell therapies patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. evidence of pregnancy or lactation moribund patient not expected to survive >24 hours unable/unwilling to deliver lung protective ventilation patient is receiving extracorporeal membrane oxygenation (ecmo)

evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. serum bilirubin > 10 mg/dl platelet count < 50,000/ml subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) history of metastatic cancer diagnosis or treatment in the past 1 year history of previous treatments with mscs or other cell therapies patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. evidence of pregnancy or lactation moribund patient not expected to survive >24 hours unable/unwilling to deliver lung protective ventilation patient is receiving extracorporeal membrane oxygenation (ecmo)

1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin > 10 mg/dl 3. platelet count < 50,000/ml 4. subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer diagnosis or treatment in the past 1 year 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive >24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)

1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin > 10 mg/dl 3. platelet count < 50,000/ml 4. subjects requiring dialysis as a result of anything other than a covid-19 infection will be excluded 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy excluding steroid use for treatment of covid-19 acute respiratory failure, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer diagnosis or treatment in the past 1 year 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 or ards. drugs that are administered under emergency use authorizations (eua) by the fda are permitted. 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive >24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)

1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin > 10 mg/dl 3. platelet count < 50,000/ml 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer in the past 3 years 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive > 24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)

1. evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. presence of shock, defined as map < 65 mmhg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain map ≥ 65 mmhg. 2. serum bilirubin > 10 mg/dl 3. platelet count < 50,000/ml 2. evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy, hiv, previous treatment for cancer, etc.) 3. history of metastatic cancer in the past 3 years 4. history of previous treatments with mscs or other cell therapies 5. patient is co-enrolled in any other ind-sponsored clinical trials for covid-19 6. evidence of pregnancy or lactation 7. moribund patient not expected to survive > 24 hours 8. unable/unwilling to deliver lung protective ventilation 9. patient is receiving extracorporeal membrane oxygenation (ecmo)